Phospholipids

[SDL] Calfactant Intratracheal Suspension 105 mg/3 mL, 210 mg/6 mL

[SDL] Poractant Alfa Intratracheal Suspension 120 mg/1.5 mL

View legend

01/09/2020 Pulmonary surfactant for treating respiratory distress syndrome in premature infants

The Ministry of Health’s Drug Advisory Committee has recommended:

• Calfactant 105 mg/3 ml and 210 mg/6 ml and poractant alfa 120 mg/1.5 ml intratracheal suspension vials for treating respiratory distress syndrome in premature infants.

Subsidy status

[R] Calfactant 105 mg/3 ml and 210 mg/6 ml, and poractant alfa 120 mg/1.5 ml intratracheal suspension vials are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

[NR] SDL does not apply to beractant 200 mg/8 ml vial.

[R] Poractant alfa does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before poractant alfa is administered, it is important to consider the availability of other suitable registered alternatives and inform the parent(s) or carer of the infant that the product is unregistered.

View legend

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration